Nolan (Host): Welcome to UK HealthCast, a podcast presented by UK healthcare.
I'm Nolan Alexander, and with me today is Dr.
Edward Cantu, the director of the Lung Service Line and lung
transplant at UK Healthcare as we talk about lung disease care.
Dr.
Cantu, how are you today?
Edward Cantu, MD: I am doing well.
Thank you.
Nolan (Host): We're so glad to have you here and let's get
to know you a little bit more.
Can you share a bit about your background And what brought you
into the field of lung care?
Edward Cantu, MD: Yeah.
well I joined the University of Pennsylvania in, 2010.
I just finished, uh, fellowship and, uh, joined as an assistant professor.
my hiring at that point was to advance lung transplantation at the university.
spent 15 years there, and during that time was able to help
double the clinical volume while, maintaining excellent outcomes.
And then I was able to do several firsts, at, uh, the University of Pennsylvania.
That was included, the first EVLP, lung transplant, the first,
DCD lung transplant, And the first low bar lung transplant.
So, My clinical experience there was phenomenal.
I worked with, some amazing, uh, faculty as well as staff and, was able to care
for over 500 transplant patient's.
and overall the work was very rewarding.
Nolan (Host): What exactly does comprehensive lung care mean to you?
Edward Cantu, MD: Comprehensive, lung care to me, means that we're
not just, technicians, we are, focused on the patient experience
And the patient's caregivers.
So, not only do we want to give high quality care, but we also
wanna focus on the experience for the family And the, patient.
So we wanna make sure that, we, identify their needs early.
Try to make the transition from, being, someone who's well, to someone who's
ill, as, easy for them as possible.
And then take them from that, portion of their experience to the, clinical
experience where we take care of them, And then establish a relationship
of care that they, will, treat us.
Like family.
So, I'm trying to create a situation here at the university that,
prioritizes the patient experience.
so that way it makes it easier for patient's, to entertain
entering the health system.
So, it can be really scary and very daunting, for families and,
patient's, to come to Lexington and to.
face the health state transitions that they're experiencing.
And, our goal is to make it easier for that transition,
easier for them to do well.
And, when they're, several years out from their care, to look back, and
think that, they had a good experience.
So for me, comprehensive care means not just taking care of the one little
thing, but to take care of everything.
Experience should be something that's not traumatizing, And that
patient's and caregivers, would then go on and, recommend to other's.
Nolan (Host): So under the North Star, the guidance right, of having the patient
first, you help treat a variety of lung conditions from routine to some more
complex that you've already talked about.
Can you go just a little bit more in depth about what these conditions may look
like and how the type of care may differ?
Edward Cantu, MD: every patient's experience is unique.
So, in all, aspects of lung care, that patient experience can be
something where, patient's have symptoms, like shortness of breath.
they can also have no symptoms and have an incidental finding
like, solitary pulmonary nodule.
whatever those, presentations are, what we are trying to create is a system where
we can take care of those patient's.
And educate, not only the patient's and caregivers, but referring providers.
so that way we can get, optimal care for these patient's.
So, the two situations I'm talking about here, can lead to two
different types of therapies, right?
So, let's say someone with a solitary pulmonary nodule.
Let's say it's small, and it's not, growing right?
And all of that would be, assessed within the lung service line.
let's then change that up a little bit.
Let's say, that nodule is first discovered, it's never been
discovered before, And that referral is made, to the lung service line.
and depending on the size, it can go to, interventionalist.
Which could be a surgeon or interventional pulmonologist, or it could go to
a pulmonologist, who will surveil.
And so, what we're trying to do is create a system where, whatever the entry point
is, the, barriers to entry are very low.
And, we create a collaborative practice with referring providers.
So that way, if.
The care can be done locally.
That means they don't have to come to Lexington.
We have a, a large population, I think, one of the, percentages I just
heard, earlier this week is a little under 90% of all patient's referred
to UK for, restrictive lung disease.
Do not live in Lexington.
And the average time to get to Lexington is, a little over two hours.
So a lot of patient's are coming from very far away.
And so, one of the things that we're trying to establish, with our
collaborating, health systems is a way for us to develop collaborative care.
So in this patient that I described.
That would be identified with a pulmonary nodule that say less than six millimeters.
We can help, surveil that, but do that maybe through telemedicine
or, do it in conjunction with the collaborating pulmonologist, just so
that way, should there be an advanced therapy that's required, we can get
that patient in, but if it's not.
We can keep that patient, local so they don't have to make a four hour drive
and, you know, come and, go back.
which may be, financially, difficult or, impossible 'cause they may not have a car.
So, there are a lot of things like that, that we're trying to work through and,
entering the health system, in a way that, makes it, easy access for as many
patient's as possible is one of our goals.
Nolan (Host): Well, let's talk about that, the near And the far as you
said, 90% outside of Lexington.
What are you seeing?
What does the landscape of lung disease look like in Kentucky?
Edward Cantu, MD: So Kentucky has, one of the highest rates at the
emphysema in the country, and one of the highest rates in the country
of coal miners, pneumoconiosis.
so, I think, A lot of changes have occurred in, potential therapies and
clinical trials that make, therapies available that are not all interventional,
meaning not surgery, not transplant, but maybe medications with clinical trials.
And what we're trying to do is increase the education.
to our referrings about these therapies so that way we can get patient's these,
therapies before their disease has progressed so far that they can't,
qualify for these therapies anymore.
And now the only therapy is transplant.
I myself am a transplant surgeon, but I would love to prevent
the need of transplant surgery in, in my patient's if I could.
Even if I could delay it few years, that's still better than transplanting them.
it seems sort of, counterintuitive, lung transplant has much better outcomes,
today than in previous decades.
but still, there are limitations.
And so the longer we can delay transplant for patient's, the better they'll
do long-term in terms of longevity.
And so, always at the root of our mission is to give the best quality and length
of life possible for our patient's.
And sometimes, you know, it's better without surgery.
hate to say that, but, is true.
and, I think that, we have a responsibility to our patient's to give.
the best care possible.
And to do that, we need to educate Referrings and, our
community what's out there.
And that's something we've been doing.
Nolan (Host): Dr.
Edward Cantu joining is.
Today from UK Healthcare Doctor, what are we doing here at UK
Healthcare to help improve care for patient's with advanced lung disease?
Edward Cantu, MD: So we are, doing, state-of-the-art lung transplants.
So, we do all the transplants that I explained early at the very
beginning of this, conversation.
So we'll do DCD, transplants, EVLP, trans.
transplants, et cetera.
So the whole gamut of these, word soup type of, highly technical transplants
we make available to our patient's.
And again, the goal is not to do X number of transplants.
The goal is to do, the number of transplants required, to treat
our patient's and have them have a good outcome, when patient's
face the end of advanced lung disease, there are no options.
the lungs are truly damaged, they're non salvageable.
There's really very limited, types of therapies for that, And the transplant
becomes, preferential treatment.
Now, survival after lung transplant on average is between five and seven
years, depending on the patient groups and that's why I said earlier, we
try to delay it as long as possible because on average, patient's will get
between five and seven additional years.
That doesn't mean patient's can't live longer, Those are just averages.
And I myself have my first patient I transplanted.
the University of Pennsylvania is, still doing well.
So, I have at least a 15 year survivor, which, I'm happy to
report, and happy to see that.
and I've had patient's that I've treated that, my predecessors had
transplanted and had lived, 20 plus years.
So long-term survival is, possible.
but there are a lot of, Risks and complications associated with the
treatment, required for lung transplant so patient's become immunocompromised.
So infections, cancers and rejection become really important.
risk factors for long-term survival.
So, we try to do everything in our power to educate our patient's, and
give them the best quality care.
So that way, my goal is.
15 years from now, I will be talking about, my first, UK
transplant, who's still doing, well.
And, I'm happy to say that the, transplants we've done have
been doing very well and, we're very pleased with, the outcomes.
And, you know, I think, we have a unique opportunity at UK to
create something truly remarkable.
Nolan (Host): what drew you specifically to UK Healthcare from your time there to
this next chapter here with UK Healthcare?
Edward Cantu, MD: Well, I think there's a lot of opportunity.
I think the faculty here And the staff are truly remarkable.
when I came to visit.
I saw the opportunity here, And the impact that we could have on the Commonwealth,
because, Kentucky has the highest rate of lung disease, in the United States, and
I saw the opportunity for us to create an infrastructure that not only would help.
With lung transplant, but could help with all of lung disease.
I hate to generalize, but everyone I've met has been salt of the earth,
good human being that, is very grateful for the care that they're given.
And every, faculty and staff member I've met here at uk, has
been, unbelievably supportive.
Unbelievably sympathetic, empathetic with their patient's, and really only want,
high quality care for their patient's.
So I think, all of these things made me feel that, coming here would allow me to
create something that's not everywhere, there are challenges in every health
system, And what I saw here was only opportunity, opportunity to create
something special for the commonwealth.
To create something that I think would leave a lasting legacy for uk.
So to me this was an easy decision based on, the quality of the
staff And the faculty and, And the really, the, desperate need of all
the patient's in the commonwealth.
Nolan (Host): and you've described it before, UK is a premier program
and has the potential in your mind to be one of the best in the country.
With that you're not only joining a new team, but you're
also building something new.
Can you tell us about the lung service line and future lung center
that you're hoping to establish?
Edward Cantu, MD: Absolutely.
so right now the lung service line, we're focusing on solitary pulmonary
nodules and lung transplant.
That's just the short term, right?
but we're also doing in-depth analysis to find out where the needs are within the
service line that we haven't identified.
So sleep studies, asthma, cf, et cetera, et cetera.
And so our goal is to be a comprehensive lung center that covers everything.
Related.
you mentioned our tagline, earlier our goal ultimately is better breathing,
better quality of life through innovation, education and clinical excellence.
So for us, what we wanna do is be able to create something that, not
only makes it, advantageous for patient's within the commonwealth,
but makes it the central focus.
For education.
So we'll have, people who want to train at uk, for research, so researchers to
come here because, all the critical infrastructures in place for us to do high
quality, high impact, disease changing research, And for us to have clinical
excellence that, is really unmatched.
And I think, like I said earlier, there's a lot of, Work that was
done before I, I, I came here.
It's not like I'm starting from scratch.
and I'm hoping to, to stand on the shoulders of those who came
before me, to be able to create something really, truly amazing.
And again, if we can do it, we'd like to see every single patient,
having more hope and feeling better.
so that way they, do not suffer from a lung disease and silence and alone.
Nolan (Host): What a great vision to have.
I love it.
Dr.
Cantu.
I, I think That is so special.
And also I'm, I'm curious, why is it unique for a surgeon to be leading
this type of service line, And what advantages does that bring to patient's?
Edward Cantu, MD: most service lines are generally run by,
physicians, not surgeons.
and in my previous, position at the University of Pennsylvania, I ran the.
ILD service line, which gave me, some understanding of how, the sausage is
made and I've taken, uh, that experience here So, it's just, surgeons are, are
generally in the operating room and they're really, really is no extra
time, for, administrative roles.
And here at uk, I've been given, some time to have an administrative role.
And so, that's why it's unique 'cause it's, as a surgeon, the more I
operate, the more patient's I can help.
And UK has, resourced, lung transplant here in a way that I don't
need to do every lung transplant.
There was a time at the University of Pennsylvania when I was doing almost
every single lung transplant, and, that was, challenging but not sustainable.
So I think this model works much better.
And I think, being able to, have, collaboration through, surgical
partners, And the medical faculty has been outstanding and, that's made it possible
for a surgeon to lead, a service line.
you know, from my perspective, understanding how, the ORs work, how,
surgeons think is beneficial to a service line because, it adds a compliment
to the general, medical leadership.
So that way there's a balance.
And I think, I'm one of the, few people to say that, surgeons know better 'cause
we don't, we like to think we do.
Like the, uh, saying goes, never in doubt.
seldom wrong.
Nolan (Host): Dr.
Cantu, you're full of humility and I love that.
As a leader, I think That is truly important.
I want you to look ahead of the future.
What are your hopes for lung care at UK over the next five to 10 years?
Edward Cantu, MD: over the next five to 10 years, we're gonna see
a complete, uh, expansion in our research and education enterprise.
So again, physicians want to train here.
Physicians wanna work here.
students want to train here.
I think that's gonna be one thing you're gonna see.
You're gonna see, an expansion in the, in the research enterprise, such
that, the number of grants here at the university, within the service
line and, affiliated collaborating, secondary service lines will increase.
and I definitely will, say that.
The number of patient's receiving appropriate care for advanced
lung disease will go up.
So there'll be more lung transplants for sure.
will be a much larger, group.
So, because of all this we'll need increased volume, we'll
need increased capacity, so.
I will see that our faculty will increase And we will be one of the
places where in the United States where, industry will wanna partner, right?
So, we wanna set up the infrastructure correctly so that way we can partner
with our, industry, sponsors, so that way we can do cutting-edge clinical trials.
We can, use, the latest devices to make sure, We are giving the best
quality, care for our patient's and give opportunity for patient's
who may have no other options.
So five to 10 years, I see this program, being such that, it'll be
the premier program in the country where everyone wants to come, whether
you're patient, faculty or staff.
Nolan (Host): If someone thinks they or a loved one may need advanced
lung care right now, what's the best way for them to begin that journey?
Edward Cantu, MD: So, it depends where they are.
So if they're outside of, the UK health system, they can talk to their provider,
whether that's a primary care provider, whether it's their pulmonologist, to let
them know that they would like a referral.
once they've received that referral that they understand we're gonna
have a collaborative practice, with their referring provider.
And we're going to set the, bar for, high level communication.
So.
That way, the referring providers not only get to read our notes, but we'll contact
them, tell them what we think is going on, how we think we can care for that patient.
And if that patient can be cared for locally with our referring
provider, we can help them with that.
so that way they don't have to drive to Lexington, make that two hour or more.
And then, we will then, make available to referring providers advanced therapies
that they may not be able to provide.
So that way, patient's get the, both of bo, both worlds.
They get high quality care locally, but they get, outstanding
advanced therapies, access.
Here at UK So, it will work well for the health system, but it
also works well for the patient.
And again, our focus is making, the patient experience, as easy as possible,
with the goal of making them, not have to jump through hoops if we can
get the high quality care locally.
And so Those are the things that I would look forward to and, and expect.
Nolan (Host): And Dr.
Cantu, you've given us so much today.
Is there anything else that you'd like to add?
Edward Cantu, MD: the main things I wanna make sure that everyone
knows is, we're here to help.
We wanna collaboratively work to make sure that every patient does well.
And so if anyone has any problems, accessing our system, please, reach out
to me and I'm happy to, to iron out those details and make sure that, the next
referral is more smooth or the next.
Uh, patient visit, is communicated, back to our referring providers because
again, we can't give high quality care if we don't have good communication
and, good teamwork, for our patient's.
And so that's, ultimately I think the, take-home message that we
want to collaborate with everyone so that way every single patient
gets the highest quality care And we don't fumble any balls.
Nolan (Host): Dr.
Cantu, thank you so much for sharing knowledge and your vision with us today.
Edward Cantu, MD: It's my pleasure.
Thank you so much, Noah.
Nolan (Host): That was Dr.
Edward Cantu.
For more information, go to UK healthcare.uk.edu.
If you enjoyed this podcast, please share it on your social channels
and check out the entire podcast library for topics of interest to you.
Thanks for listening to UK Health Cast, a podcast from UK Healthcare.